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Purpose. The purpose of this study was to determine the permeation
parameters of thalidomide and three of its N-alkyl analogs and to
establish a correlation between the physicochemical properties of
these compounds and their percutaneous rates of absorption.
Methods. In vitro permeation studies were performed from buffer,
n-alkanols and various mixed components using vertical Franz diffu-
sion cells fitted with human epidermal membranes.
Results. Measured steady-state fluxes indicate that N-methyl thalido-
mide is a far better penetrant of human skin than the “parent mol-
ecule”. However, fluxes through skin drop off markedly from that of
the methylated compound when the chain length is extended to pro-
pyl and pentyl. However, they remain well above the flux of thalido-
mide, which is less than 0.025 g/cm2/h.
Conclusions. The best skin permeant of this series was the N-methyl
analog, which also exhibited the highest water (buffer) solubility
compared to thalidomide, and the N-propyl and N-pentyl analogs.
The N-propyl and N-pentyl analogs were more lipid soluble and ex-
hibited higher partition coefficient values than the N-methyl analog.
From all the permeability data using buffer, a series of n-alkanols and
various combinations of solvents and enhancers as vehicles, the more
water-soluble compound and not the more lipid soluble one was the
best skin permeant.
KEY WORDS: thalidomide; N-alkyl analogs; physicochemical prop-
erties; transdermal; percutaneous delivery.
INTRODUCTION
Thalidomide is a proven inhibitor of the biological syn-
thesis of tumor necrosis factor alpha (TNF-) and is believed
to rely on this action for its suppression of the wasting of
tissue that otherwise accompanies leprosy and other diffuse
connective tissue disorders such as rheumatoid arthritis (1).
There is good reason to believe that tissue wasting and other
joint
damage done by arthritis can also be lessened or stopped
upon use of this drug (2). However, the systemic levels, which
have to be attained to gain this benefit from thalidomide in
the instance of rheumatoid arthritis, are associated with seri-
ous untoward effects. The question we would like to answer,
therefore, is whether thalidomide or a similarly acting com-
pound can be delivered preferentially to local areas by apply-
ing it topically. The goal here is to assess the possibility of
delivering a potent TNF- inhibitor through skin as the first
step in getting an effective agent into the synovial fluid of an
infected rheumatoid arthritis joint. The ultimate intent would
be to inhibit TNF- production within the joints beneath and
around the site of application without raising circulating lev-
els of a drug to a point of concern. Among other possible
benefits, percutaneous delivery would level out the peaks and
valleys in blood levels seen with discrete oral dosages and this
itself might lessen toxicity. Drug concentrations that can be
achieved in deep tissues beneath the application (i.e. joints,
masculature, etc.) are expected to be higher than can be
achieved by oral administration of the same amount of drug
(3).
Generally, molecules containing multiple hydrogen
bonding centers and/or strong dipoles are high melting due to
strong intermolecular crystalline self-association. Such mol-
ecules have little tendency to dissolve in organic phases and,
consequently, their partitioning into the lipoidal barrier
phases of the skin is minimal. Their permeation rates tend to
be low even from their saturated solutions. Clearly, a low
capacity to dissolve in the transport phases is a major obstacle
to percutaneous delivery.
The easiest way to determine whether a drug can be
delivered percutaneously is to assess the drugs in vitro per-
meability through skin. Thus, in vitro diffusion cell experi-
ments were run to determine the skin absorption of thalido-
mide and closely structurally related analogs.
MATERIALS AND METHODS
Thalidomide and three of its odd chain N-alkyl analogs
(methyl, propyl and pentyl), the structures of which appear in
Fig. 1, were synthesized and identified as described previously
(4). HPLC-grade acetonitrile and methanol were purchased
from Fisher Scientific (Pittsburg, PA, USA) and used in the
mobile phase of the HPLC method. For permeability studies,
double-distilled deionized water and reagent grade organic
solvents (Aldrich, Milwaukee, WI, USA) were used as re-
ceived. Human female skin was obtained from the Anatomic
Donation Program of the University of Michigan’s Medical
School.
Chromatographic Procedure
Thalidomide and its N-alkyl analogs were assayed by
HPLC as described previously (4). Briefly, the HPLC con-
sisted of a Beckman 114M solvent delivery system and a Spec-
traflow 783 variable wavelength UV detector set at 220 nm. A
C8 Spheri-5 micron cartridge (220 × 4.6 mm) with a guard
column was used. The mobile phase consisted of 25% aceto-
nitrile/water for thalidomide and N-methyl thalidomide and
35% and 45% acetonitrile for the N-propyl and N-pentyl ana-
logs, respectively. The flow rate was set at 1.2 ml/min.
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Preparation of Donor Solutions
The donor solutions of thalidomide and its N-alkyl ana-
logs were obtained by equilibrating excess amounts of each of
the compounds with phosphate buffer (pH 6.4), a series of
n-alcohols and mixed solvents and/or penetration enhancers
after placing slurries of the test compounds individually into
stoppered, water-jacketed, glass containers. The temperature
was maintained at 32 °C by circulating water through the
jackets from a constant temperature water bath. The slurries
were vigorously and continuously mixed for 24 h using mag-
netic stirring bars. Preliminary work indicated that under the
conditions used, a saturated state was achieved well within
one day. Therefore, aliquots for assay were taken after 24 h of
vigorous mixing. These samples were filtered through filters
(PTFE filter media with Polypropylene housing, 0.45 m pore
size, Whatman Inc., Haverhill, MA, USA) preconditioned to
the experimental temperature. The initial portion of the fil-
trate was discarded to discount possible absorption of the
compounds on the film or filtering apparatus. A measured
volume (300 l) of clear filtrate was then drawn and added to
the donor compartment.
Skin Preparation
Samples of split-thickness skin were removed from the
thigh of female cadavers within 24 h postmortem, with the aid
of a dermatome set at 250 m. The epidermal layer was sepa-
rated from a split-thickness skin section by immersing the skin
section in 60 °C water for 1 min. The epidermal layer was
gently teased away from the remaining tissue with forceps.
The skin sections were cut into squares, wrapped in plastic
film and stored in a freezer at −20 °C until they were needed.
The frozen skin pieces were thawed and visually inspected for
defects before mounting them within the diffusion apparatus.
All frozen tissue was used within 2 months of its receipt.
Skin Permeation Method
Vertical Franz diffusion cells with a 4-ml capacity recep-
tor compartment and a 0.8-cm2 diffusion area were used in
the permeation studies. The epidermal layer of the skin was
mounted carefully onto the lower half of the cells of the dif-
fusion apparatus with the stratum corneum facing up in the
direction of the donor compartment. A donor compartment
was fastened to its respective receptor compartment with a
clamp, with the skin acting as a seal between the half-cells.
The receptor compartments were then filled with isotonic
phosphate buffer (pH 6.4). Care was taken to see that there
were no consequential air bubbles left in the compartments.
Skin surface temperature was maintained at 32 °C by circu-
lating water from a constant temperature water bath (Lauda
K-2/RD, Beckman Instruments, Inc., Fullerton, CA, USA)
through the jacket of the lower compartment (5). The recep-
tor cell compartments were filled and equilibrated with buffer
1 h before adding the drug-containing solution to the donor
compartment. Stirring was maintained during the equilibra-
tion period and the remainder of the experiment. A small
magnetic stirring bar was placed at the bottom of each recep-
tor compartment to accomplish this. The donor compartment
was filled with 300 l of freshly prepared saturated solution of
the drug and covered immediately with Parafilm to prevent
evaporation of volatile components of the applied medium
during the absorption experiment. At 5, 7, 9, 11, 13, and 15 h,
the entire receptor volume was withdrawn and replaced with
fresh buffer at 32 °C. This was done to insure that sink con-
ditions existed throughout each experiment. Samples were
directly assayed by HPLC to determine the drug concentra-
tions in the receiver fluid. The permeation data were plotted
as the cumulative amount of drug penetrated through skin as
a function of time. The steady-state flux was determined from
the slope of the linear portion of the cumulative amount-time
plot. Permeation studies were performed using buffer and
n-alkanols as vehicles. To enhance the skin flux and simulta-
neously determine which analog in the study penetrated the
skin best, various combinations of solvents and penetration
enhancers were combined and used as vehicles. The compo-
sitions of these formulations, A-C, were chosen based on the
results of earlier experiments aimed at formulating thalido-
mide into a percutaneous application. Formulation A com-
prised of 70% isopropanol, 10% n-methyl pyrrolidone, 10%
n-octanol, 5% citric acid and 5% isopropyl myristate ester
(IPM). The composition of formulation B was 80% ethanol,
10% n-octanol, 5% citric acid and 5% IPM. Formulation C
comprised of 57.5% water, 40% ethanol and 2.5% n-octanol.
RESULTS
The 32 °C aqueous (g/ml) and octanol (mg/ml) solubili-
ties, melting points and octanol/water partition coefficients
(Koct) of thalidomide and its N-alkyl analogs are summarized
in Table I. Methylation of the thalidomide molecule en-
hanced the aqueous solubility 6-fold, but as the alkyl chain
length is further extended from methyl to pentyl, the aqueous
solubility decreased exponentially. The destabilization of the
crystalline structure with increasing alkyl chain length led to
an increase in lipophilicity of the analogs as evident in their
higher octanol solubilities and octanol/water partition coeffi-
cients. By adding a methyl group to the thalidomide structure,
the melting point drops by over 100 °C and upon increasing
the alkyl chain length to five -CH2- units, the melting points
decrease linearly. When the experimental permeability coef-
ficients from water are plotted against the partition coeffi-
cients (Fig. 2) a strong correlation is found between them.
This correlation reflects the fact that skin partitioning is an
element of the mass transport process, which share a common
dependency with octanol/water partitioning. This alone indi-
Fig. 1. Structural formula of thalidomide and its N-alkyl analogs.
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cates that the skin is acting to a first good approximation as a
lipophilic barrier.
The predicted permeability coefficients (Kp) of thalido-
mide and its N-alkyl analogs from their saturated aqueous
solutions (pH 6.4) are summarized in Table II. The maximal
flux of a given solute from a particular vehicle can be esti-
mated from the product of its permeability coefficient across
the membrane and its solubility in the vehicle. The maximal
predicted and experimental fluxes for thalidomide and its N-
alkyl analogs from an aqueous vehicle (buffer) are given in
Table II. These fluxes were found to increase when the tha-
lidomide molecule (log Koct  0.49) was methylated (log Koct
 1.15) and decreased when the alkyl chain length was ex-
tended to propyl and pentyl (log Koct  2.11 and 3.01, re-
spectively). Similar results were observed for NSAIDs (8).
The experimental determined flux values are the mean ±
standard deviation (SD) of six diffusion experiments. The flux
of thalidomide was so low that it could not be detected by the
HPLC method. The limit of detection of the HPLC method
was 0.01 g/ml. Thus, the flux of thalidomide was less than
0.025 g/cm2/h. The fluxes of thalidomide and its N-alkyl ana-
logs were all statistically different from one another at p <
0.01 with one exception. The fluxes of N-methyl thalidomide
and N-propyl thalidomide were statistically different only at a
90% confidence level (p < 0.1).
The fluxes of thalidomide and its N-alkyl analogs
through human skin at 32 °C using a series of n-alkanols as
solvents are summarized in Table III. These data are plotted
in Fig. 3 as the steady-state flux (g/cm2/h) against the num-
ber of carbons in the n-alkanols. Declining fluxes with in-
creased alkanol chain length can be seen with every one of the
four test compounds. Thalidomide is the poorest penetrant
from every one of the alkanols and N-methyl thalidomide
turns out to be the most facile penetrant of the series in study.
The steady-state fluxes of thalidomide and its N-alkyl
analogs, from formulations A-C can be seen in Table III and
Fig. 4. To make comparisons between the four test com-
pounds, the same skin specimen was used for the compounds
applied within each individual formulation and therefore nor-
malization of fluxes was not necessary (9). For comparisons
between formulations, normalization of fluxes would be ap-
propriate (10,11). The flux of N-methyl thalidomide is statis-
tically higher (p < 0.05) than that of thalidomide and the other
analogs in all three formulations.
DISCUSSION
We are working on the hypothesis that thalidomide or an
analog thereof can be delivered into tissues beneath the skin
from topical applications in sufficient quantity to arrest the
degenerative changes associated with rheumatoid arthritis.
The purpose of this study was to determine the permeation
parameters of thalidomide and several N-alkyl analogs from
water to obtain baseline permeation data that allow compari-
sons with other compounds. We also set about testing a series
of n-alkanols and various other vehicles to take measures of
the intrinsic percutaneous permeabilities of these drugs as a
step towards predicting their potentials as topical therapeutic
systems. Our intent was also to establish a correlation be-
tween the physicochemical properties of these compounds
and their percutaneous rates of absorption.
Compounds that are absorbed through skin in vivo are
mainly taken up and cleared systemically by blood vessels
directly beneath the epidermis. Thus, compounds do not have
to penetrate the full thickness of the skin (epidermis and
dermis) before entering the vasculature system. Accordingly,
for in vitro permeation studies, the epidermis (including the
stratum corneum) is often if not usually separated from the
underlying dermis using a heat separation technique (12).
This technique cannot confidently be applied to hairy skin
because the hair shafts are anchored firmly in and remain in
the dermis, creating holes in the epidermal membrane as the
dermis is pulled away. To obviate all concern here, only skin
from female cadavers was used in this study. Harrison and
co-workers (13) examined the integrity of the barrier layer
following storage after various time periods. No differences
Fig. 2. Logarithmic plot of experimentally derived aqueous perme-
ability coefficient (Log Kp) vs. partition coefficient (Log Koct) for
thalidomide and its N-alkyl analogs.










Thalidomide 275 0.49 61.4 0.07
N-methyl thal. 159 1.15 370.4 2.64
N-propyl thal. 136 2.11 59.4 6.21
N-pentyl thal. 105 3.01 9.0 20.19
a Source: Data from Ref. 4.
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were found between measurements of in vitro percutaneous
penetration of tritiated water in skin stored at −20 °C for up
to 466 days vs. fresh skin stored at 10 °C and used within 2–3
days of autopsy, indicating the barrier properties inherent in
skin remain intact under the conditions of storage used in this
work.
Ethanol is one of the most commonly used skin perme-
ation enhancers and its use as part of a co-solvent system with
water has been observed to increase permeation of a wide
range of drugs through human and animal skin both in vivo or
in vitro. Several compounds are commercially delivered from
transdermal systems having alcohol-containing reservoirs
(14). Estradiol and fentanyl are two transdermal drugs, which
appears in formulations containing ethanol as a penetration
enhancer. It was hypothesized that this solvent or a closely
related compound might prove to be of benefit with respect to
delivering thalidomide. Systematic studies were begun using a
range of homologous n-alkanols to explore the hypothesis. It
is also known that the degree of flux enhancement may in-
crease upon blending a nonpolar, long-chain enhancer into
ethanol or isopropanol (15). It has been reasoned that, while
the polar enhancers traverse the skin, the nonpolar enhancers
are largely retained in the stratum corneum, aspects that ap-
pear to make such combinations superior enhancer systems
(16). In terms of toxicology, ethanol and isopropanol are the
most acceptable of the short-chain alcohols. However, to bet-
ter understand the structural requirements for enhancement,
and to determine which compound in study penetrates the
skin best, flux studies were performed using all alkanols that
are liquid at room temperature, e.g. alkanols up to a chain
length of twelve, irrespective of toxicity. Truly extraordinary
results were obtained upon doing so.
Steady-state fluxes of thalidomide and its three N-alkyl
analogs through human skin when each of the compounds
was administered as a saturated solution in each of the al-
kanols are presented in Fig. 3. The first pattern that emerges
upon viewing the data is that the alkanols become increas-
ingly less effective vehicles as their alkyl chain length is ex-
tended. Although there is variability in the data and some
minor reversals in the general pattern, a trend to declining
permeability as the alkanol chain is lengthened is seen with
every one of the four test compounds. The experimental
fluxes of thalidomide and its N-alkyl analogs from buffer, a
series of n-alkanols and different formulations (Tables II and
III) showed clearly that thalidomide is the poorest penetrant
from every one of these donor vehicles. These data also in-
dicate that N-methyl thalidomide is the most facile penetrant
from saturated solutions throughout the alkanol series and







Experimental flux ± SD
(g/cm2/h)
Thalidomide 0.119 × 10−3 0.007 —c
N-methyl thal. 0.287 × 10−3 0.105 0.43 ± 0.08
N-propyl thal. 0.929 × 10−3 0.055 0.34 ± 0.13
N-pentyl thal. 2.730 × 10−3 0.025 0.18 ± 0.06
a Calculating according to Ref. 6.
b Calculating according to Ref. 7.
c Flux was too low to be detected by HPLC method.
Fig. 3. Steady-state fluxes of thalidomide and its N-alkyl analogs from saturated n-alcohol solutions plotted against the alcohol chain length.
These data are the mean ± standard deviation (SD) of 3 diffusion experiments.
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from buffer. This is not a phenomenon strictly associated with
alkanols and buffer, the same happened when the three ve-
hicles identified as A, B, and C was employed. Formulations
A–C were selected based on earlier experiences we had for-
mulating thalidomide for percutaneous application. The bar
plots in Fig. 4 indicate that, relative to thalidomide, there is
initially an extraordinary increase in steady-state flux when
the compound is methylated. However, fluxes through skin
fall back markedly when the chain length is extended to pro-
pyl and pentyl. N-Methyl thalidomide has the highest maxi-
mum flux, the smallest log Koct and octanol solubility, but the
highest water solubility of the N-alkyl analogs. The maximum
flux decreased in the order N-methyl, N-propyl, N-pentyl, and
thalidomide. This rank order in skin permeability correspond
well with the results from a study done by Le and Lippold
(17) where methyl nicotinate has the highest maximum flux,
the smallest log Koct, but the highest water solubility. Roy and
co-workers (18) also showed that the skin flux of alkyl p-
aminobenzoates was in the order methyl > ethyl > butyl.
Again, the methyl ester has the lowest silicone/water partition
coefficient but the highest solubility in water. The rank order
in skin permeability for thalidomide and its N-alkyl analogs
(N-methyl > N-propyl > N-pentyl > thalidomide) from all the
different donor vehicles also correlates well with the maxi-
mum predicted flux (Table II) when the buffer solubility is
taken into account. No correlation was observed between
lipid solubility and skin permeability. Waranis and Sloan (19)
also noted that there is no correlation between lipid solubility
of a prodrug and relative ability to deliver a drug through the
skin. They also stated that the best prodrugs of the series in
terms of delivering 6-mercaptopurine (6-MP) through the
skin, regardless of the vehicle, has been attributed mainly to
the increased water solubility of these two prodrugs com-
pared with that of 6-MP and the other prodrugs.
CONCLUSION
Since the stratum corneum is basically a lipophilic bar-
rier, drug lipophilicity is regarded as one of the key param-
eters which controls drug skin permeation and thus it is ex-
pected that more lipophilic drug derivatives could show better
partitioning and solubility into the stratum corneum which
could result in enhanced skin permeation. However, due to
the biphasic nature of the skin, a balance should exist between
the lipid and water solubilities of drugs needed for enhanced
transdermal drug delivery. Based on experimental data, au-
thors have pointed out that water solubility plays a role as
important as lipophilicity in the skin permeation process (19–
21). From all the permeability data of thalidomide and its
N-alkyl analogs, using water, a series of n-alkanols and vari-
ous combinations of solvents and enhancers as vehicles, it is
clear that N-methyl thalidomide is the best permeant of this
series. The N-propyl and N-pentyl analogs exhibit signifi-
cantly higher lipid solubility and lower aqueous solubility
than N-methyl thalidomide. The results in this study show
that in each donor vehicle the more water-soluble compound
Table III. Steady-State Flux Values of Thalidomide and its N-Alkyl Analogs from a Series of n-Alcohols and Three Different Formulations
Vehicle








Methanol (C1) 0.147 ± 0.005 4.498 ± 0.220 1.730 ± 0.768 2.059 ± 0.086
Ethanol (C2) 0.066 ± 0.053 2.819 ± 0.391 0.378 ± 0.226 0.250 ± 0.139
Propanol (C3) 0.039 ± 0.002 0.822 ± 0.096 0.621 ± 0.058 0.178 ± 0.096
Butanol (C4) 0.037 ± 0.016 0.813 ± 0.196 0.123 ± 0.03 0.083 ± 0.044
Pentanol (C5) 0.039 ± 0.014 0.722 ± 0.034 0.291 ± 0.134 0.086 ± 0.01
Hexanol (C6) 0.028 ± 0.007 0.468 ± 0.037 0.347 ± 0.111 0.065 ± 0.036
Heptanol (C7) 0.029 ± 0.002 0.250 ± 0.016 0.129 ± 0.023 0.192 ± 0.084
Octanol (C8) 0.035 ± 0.010 0.185 ± 0.003 0.164 ± 0.022 0.124 ± 0.038
Nonanol (C9) 0.036 ± 0.018 0.174 ± 0.008 0.225 ± 0.062 0.126 ± 0.077
Decanol (C10) 0.018 ± 0.001 0.351 ± 0.220 0.201 ± 0.081 0.117 ± 0.007
Undecanol (C11) 0.010 ± 0.003 0.223 ± 0.040 0.101 ± 0.047 0.196 ± 0.091
Dodecanol (C12) 0.025 ± 0.004 0.172 ± 0.030 0.063 ± 0.016 0.169 ± 0.023
Formulation A 0.156 ± 0.021 2.070 ± 0.282 0.666 ± 0.141 0.096 ± 0.048
Formulation B 0.323 ± 0.193 2.710 ± 0.538 0.563 ± 0.172 0.244 ± 0.096
Formulation C 0.831 ± 0.218 6.540 ± 0.448 2.125 ± 0.293 2.142 ± 0.178
Fig. 4. Bar plot showing a mean (n  3) steady-state flux ± standard
deviation (SD) of thalidomide and its N-alkyl analogs from different
formulations.
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and not the more lipid soluble one was more efficient in pen-
etrating the skin. The high transdermal flux of N-methyl tha-
lidomide is associated with its high aqueous solubility, low
molecular weight, low melting point and moderately high li-
pophilicity. In conclusion, this study showed that increased
lipophilicity or partition coefficient values did not result in a
higher skin flux, but the highest flux through skin is achieved
by the more lipophilic analog that showed the highest water
solubility.
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